About Capricor Therapeutics, Inc. - Common Stock (CAPR)
Capricor Therapeutics is a clinical-stage biotechnology company focused on developing innovative cellular therapeutics to treat rare and chronic diseases. The company primarily works on harnessing the potential of stem cell-derived therapies, with a particular emphasis on cardiac and musculoskeletal conditions. Capricor aims to advance its proprietary technologies through rigorous research and development, striving to bring transformative treatment options to patients with unmet medical needs. By leveraging its expertise and pioneering spirit, Capricor seeks to make significant contributions to the field of regenerative medicine. Read More
NEW YORK - August 22, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK - August 21, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
If You Suffered Losses Exceeding $50,000 in Capricor between October 9, 2024 and July 10, 2025 Securities Litigation Partner James (Josh) Wilson Encourages you to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
NEW YORK - August 20, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
NEW YORK - August 19, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
NEW YORK - August 18, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, inclusive.
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648
NEW YORK - August 15, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
NEW YORK - August 14, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK - August 13, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
